TFS Financial (NASDAQ:TFSL) reported quarterly earnings of $0.06 per share. This is a 40 percent decrease over earnings of $0.10 per share from the same period last year.
Biogen Announced Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer’s Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc.
